Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: A report from an international DLBCL rituximab-CHOP consortium program study

Carlo Visco, Alexander Tzankov, Zijun Y. Xu-Monette, Roberto N. Miranda, Yu Chuan Tai, Yan Li, Wei Min Liu, Emanuele S G d'Amore, Yong Li, Santiago Montes-Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Huan You Wang, Cherie H. Dunphy, Eric D. His, X. Frank Zhao, William W L ChoiXiaoying Zhao, J. Han van Krieken, Qin Huang, Weiyun Ai, Stacey O'Neill, Maurilio Ponzoni, Andres J M Ferreri, Brad S. Kahl, Jane N. Winter, Ronald S. Go, Stephan Dirnhofer, Miguel A. Piris, Michael B. Møller, Lin Wu, L. Jeffrey Medeiros, Ken H. Young

Research output: Contribution to journalArticle

Abstract

Diffuse large B-cell lymphoma can be classified by gene expression profiling into germinal center and activated Bcell subtypes with different prognoses after rituximab-CHOP. The importance of previously recognized prognostic markers, such as Bcl-2 protein expression and BCL2 gene abnormalities, has been questioned in the new therapeutic era. We analyzed Bcl-2 protein expression, and BCL2 and MYC gene abnormalities by interphase fluorescence in situ hybridization in 327 patients with de novo disease treated with rituximab-CHOP. Isolated BCL2 and MYC rearrangements were not predictive of outcome in our patients as a whole, but only in those with the germinal center subtype of lymphoma. The prognostic relevance of isolated MYC rearrangements was weaker than that of BCL2 isolated translocations, but was probably limited by the rarity of the rearrangements. Seven of eight patients with double hit lymphoma had the germinal center subtype with poor outcome. The germinal center subtype patients with isolated BCL2 translocations had significantly worse outcome than the patients without BCL2 rearrangements (P=0.0002), and their outcome was similar to that of patients with the activated B-cell subtype (P=0.30), but not as bad as the outcome of patients with double hit lymphoma (P

Original languageEnglish
Pages (from-to)255-263
Number of pages9
JournalHaematologica
Volume98
Issue number2
DOIs
Publication statusPublished - Feb 1 2013

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Visco, C., Tzankov, A., Xu-Monette, Z. Y., Miranda, R. N., Tai, Y. C., Li, Y., Liu, W. M., d'Amore, E. S. G., Li, Y., Montes-Moreno, S., Dybkær, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Wang, H. Y., Dunphy, C. H., His, E. D., Zhao, X. F., ... Young, K. H. (2013). Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: A report from an international DLBCL rituximab-CHOP consortium program study. Haematologica, 98(2), 255-263. https://doi.org/10.3324/haematol.2012.066209